News | September 17, 2009

New XIENCE V Stent Trial Data to be Presented at TCT

September 18, 2009 ¬– Abbott has announced the company's schedule of key news announcements and events during the Transcatheter Cardiovascular Therapeutics (TCT) 2009 conference in San Francisco, Sept. 21-25.

Highlights include the presentation of new scientific data on the company's XIENCE V Everolimus-Eluting Coronary Stent System. One-year results from the SPIRIT IV trial, which will be presented as a late-breaking clinical trial on Wednesday, Sept. 23, will provide information about the efficacy and safety of XIENCE V compared to Boston Scientific's TAXUS Paclitaxel-Eluting Coronary Stent System. In addition, three-year results from the SPIRIT III trial will provide insights about the long-term safety and efficacy of XIENCE V.

Key presentations and events are as follows (all events are at the Moscone Center unless otherwise noted):

Monday, Sept. 21
• “SPIRIT III: Three-year results from SPIRIT III, a large-scale pivotal clinical trial comparing XIENCE V to TAXUS in 1,002 patients,” will be presented by Gregg W. Stone, M.D., of Columbia University Medical Center and principal investigator of the SPIRIT III trial, during the Drug-Eluting Stent (DES) Summit at 5:43 p.m. in Room 104.

Tuesday, Sept. 22
• ABSORB: During the DES Summit in Room 104, John A. Ormiston, M.D., of Mercy Hospital, New Zealand, and Patrick W. Serruys, M.D., Ph.D., of Thoraxcentre, Erasmus University Hospital, the Netherlands, will discuss two-year data from the first stage of Abbott's ABSORB trial, the world's first trial to study a fully bioabsorbable drug-eluting device for coronary artery disease. Dr. Ormiston will provide a clinical overview at 4:21 p.m., and professor Serruys will review serial angiography, intravascular ultrasound (IVUS) and optical coherence tomography (OCT) imaging results at 4:31 p.m.

Wednesday, Sept. 23:
• The Fourth Revolution: At the "Fully Bioabsorbable Devices" breakfast symposium from 6:30-8 a.m. in room 124, Abbott will provide an update on the company's bioabsorbable device program being studied outside the United States. Speakers include Dr. Ormiston; professor Serruys; Ian T. Meredith, MBBS, Ph.D., of Monash Medical Centre, Australia; and Renu Virmani, M.D., of CVPath Institute.

• SPIRIT IV: One-year results from the SPIRIT IV study will be presented by Dr. Stone during the first late-breaking clinical trials session of the TCT conference at 11 a.m. in the Esplanade Ballroom. SPIRIT IV is the largest randomized clinical trial ever presented between two drug-eluting stents, with 3,690 patients - including more than 1,000 patients with diabetes. Dr. Stone is the principal investigator of the SPIRIT IV trial.

• TCT Investor Meeting: Abbott will host an investor meeting from 12:45 p.m. to 2 p.m. to review the one-year results from SPIRIT IV and provide an overview of the company's vascular business and pipeline. The live Web cast of the meeting will be available from Abbott's Investor Relations Web site at www.abbottinvestor.com.

• The SPIRIT of Leadership: During the "New DES Results and Future Innovations" evening symposium from 7 p.m. to 10 p.m. at the Hilton San Francisco, Grand Ballroom, Dr. Stone will discuss the SPIRIT IV results and David Cox, M.D., of Lehigh Valley Hospital, will discuss the SPIRIT III results. In addition, John A. McPherson, M.D., of Vanderbilt Heart and Vascular Institute, will present data from XIENCE EXCEED, a post-approval study evaluating the stent's acute performance, deliverability and resource utilization in the catheterization lab. The symposium will be moderated by Ron Waksman, M.D., of the Washington Hospital Center.

Thursday, Sept. 24:
• Vessel Closure: During the "Modern Approaches to Vascular Access Management" breakfast symposium from 6:30 a.m. to 8 a.m. in room 123, experts will review the latest clinical information for improving patient care and driving hospital efficiency through the use of vascular closure devices and discuss the future of closure devices. Speakers include David Lee, M.D., of Stanford University Medical Center; Thomas Stuver, M.D., of Rochester General Hospital; Ramin Ebrahimi, M.D., of UCLA Medical Center and Greater Los Angeles VA Medical Center; and William Jordan Jr., M.D., of University of Alabama at Birmingham Hospital.

• PROSPECT: Findings from Abbott's PROSPECT trial will be presented by Dr. Stone at 12:15 p.m. during the late-breaking trials session in the Esplanade Ballroom. PROSPECT is a first-of-its-kind natural history study designed to help advance scientific understanding around vulnerable plaque and its possible role in causing heart attacks. Approximately 700 patients with acute coronary syndrome were enrolled into the study at centers in the United States and Europe.

Throughout the week, Abbott will showcase its latest products at booth 1316 in the exhibit hall. The booth also will feature Abbott's vascular pipeline, as well as resources and programs for physicians and patients, such as Abbott's new Women's Heart Health Initiative.

For more information: www.abbott.com

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init